Alkermes plc (ALKS)

Alkermes plc is a global biopharmaceutical company that specializes in developing innovative medicines to address unmet needs in the fields of neuroscience and oncology. The company was founded in 1987 and is headquartered in Dublin, Ireland, with significant operations in Waltham, Massachusetts, USA. Known for its expertise in drug delivery technologies, Alkermes has developed a strong portfolio of products aimed at treating serious chronic conditions, including schizophrenia, bipolar disorder, addiction, and multiple sclerosis. As of the most recent information available, Alkermes' CEO is Richard Pops, who has been a part of the company since the early 1990s, playing a pivotal role in its strategic growth and transformation. Alkermes is publicly traded on the NASDAQ under the ticker symbol ALKS. The company’s revenue varies yearly as it invests heavily in research and development to bring new therapeutic options to market. Alkermes is committed to advancing scientific research and embracing a patient-centric approach to improve lives, making it a noteworthy organization within the biopharmaceutical industry.